Logo Logo
Baumueller, Eva (2009): Electromyogram-Biofeedback in Patients with Fibromyalgia A Randomized Controlled Trial. Dissertation, LMU München: Medizinische Fakultät



Electromyogram-Biofeedback in Patients with Fibromyalgia: A Randomized Controlled Trial Objective: To evaluate the effectiveness of EMG-biofeedback in patients with Fibromyalgia. Design: The study design was a randomized controlled pilot trial with blinded assessors and three points of assessment: before intervention (baseline, T0), at the end of treatment (T1) and a 3-months follow-up (T2). Setting: Outpatient clinic. Patients: Patients from the waiting list of the Fibromyalgia day hospital program fulfilling the inclusion criteria. Intervention: During eight weeks, 14 sessions of EMG-biofeedback training versus usual care only. Outcome Measures and Analysis: For primary outcome, the disease specific health status was followed using the Fibromyalgia Impact Questionnaire (FIQ). Secondary outcome measures comprise assessment of pain (Tender Point Score), tenderness (Tender Point Count = number of Tender Points, Pain Pressure Threshold), generic health status (SF-36), Patients’ Global Clinical Impression of Change and psychic impact (Beck depression Inventory, Symptom Checklist 90-Revised). Effects were analyzed with sensitivity statistics (effect size, ES), parametric and nonparametric tests. Results: The data of 36 patients with complete follow-up data could be analyzed. EMG-EMG-biofeedback did not improve health status of patients with Fibromyalgia (FIQ, T1: ES = 0.02, p = 0.95, T2: ES = 0.26, p = 0.43). Also, the secondary outcome measures, with the exception of the pressure pain threshold (T1: ES = 0.26, p = 0.014), showed no superiority of EMG-biofeedback in addition to usual care compared to usual care alone. Conclusion: In the treatment of patients with Fibromyalgia, EMG-biofeedback training in addition to usual medical care is not superior to usual medical care alone.